Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

Illinois Compiled Statutes

 ILCS Listing   Public Acts  Search   Guide   Disclaimer

Information maintained by the Legislative Reference Bureau
Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process. Recent laws may not yet be included in the ILCS database, but they are found on this site as Public Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the Guide.

Because the statute database is maintained primarily for legislative drafting purposes, statutory changes are sometimes included in the statute database before they take effect. If the source note at the end of a Section of the statutes includes a Public Act that has not yet taken effect, the version of the law that is currently in effect may have already been removed from the database and you should refer to that Public Act to see the changes made to the current law.

410 ILCS 240/3.5

    (410 ILCS 240/3.5)
    Sec. 3.5. Metachromatic leukodystrophy.
    (a) The Department shall provide all newborns with screening tests for the presence of metachromatic leukodystrophy. The testing shall begin within 6 months after the occurrence of all of the following milestones:
        (1) Unless the federal Food and Drug Administration
approves a screening test for metachromatic leukodystrophy using dried blood spots, the development and validation of a reliable methodology for screening newborns for metachromatic leukodystrophy using dried blood spots and a methodology for conducting quality assurance testing of the screening test.
        (2) The availability of any necessary reagent for a
metachromatic leukodystrophy screening test.
        (3) The establishment and verification of relevant
and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for Federal Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required.
        (4) The availability of quality assurance testing and
comparative threshold values for metachromatic leukodystrophy screening tests.
        (5) The acquisition and installation by the
Department of equipment necessary to implement metachromatic leukodystrophy screening tests.
        (6) The establishment of precise threshold values
ensuring defined disorder identification of metachromatic leukodystrophy.
        (7) The authentication of pilot testing indicating
that each milestone described in paragraphs (1) through (6) has been achieved.
        (8) The authentication of achieving the potential of
high throughput standards for statewide volume of each metachromatic leukodystrophy screening test concomitant with each milestone described in paragraphs (1) through (4).
    (b) To accumulate the resources for the costs, including start-up costs, associated with metachromatic leukodystrophy screening tests and any follow-up programs, the Department may require payment of an additional fee for administering a metachromatic leukodystrophy screening test under this Section. The Department may not require the payment of the additional fee prior to 6 months before the Department administers metachromatic leukodystrophy screening tests under this Section.
(Source: P.A. 103-368, eff. 1-1-24.)